Velpatasvir
Tags:
drug
small molecule
PubChem: 67683363 67683363 Related interactions
Related publications
Title
Author
Type
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong
Research
Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19 Vishal Mevada, Pravin Dudhagara, Himani Gandhi, Nilam Vaghamshi, Urvisha Beladiya, Rajesh Patel
Research
Nucleotide Analogues as Inhibitors of Viral Polymerases Jingyue Ju, Shiv Kumar, Xiaoxu Li, Steffen Jockusch, James J. Russo
Research
Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection Shufeng Liu, Christopher Z. Lien, Prabhuanand Selvaraj, Tony T. Wang
Research
Combined Deep Learning and Molecular Docking Simulations Approach Identifies Potentially Effective FDA Approved Drugs for Repurposing Against SARS-CoV-2 Muhammad U Anwar, Farjad Adnan, Asma Abro, Rayyan A Khan, Asad U Rehman, Muhammad Osama, Saad Javed, Ahmadullah Baig , Muhammad R Shabbir, Muhammad Z Assir
Research
Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste James T. Gordy, Kaushiki Mazumdar, Noton K. Dutta
Other
Potential Drugs Targeting Nsp16 Protein May Corroborates a Promising Approach to Combat SARSCoV-2 Virus Uma Shankar, Neha Jain, Prativa Majee, Subodh Kumar Mishra, Brijesh Rathi, Amit Kumar
Research
Repurposing of FDA Approved Drugs for the Identification of Potential Inhibitors of SARS-CoV-2 Main Protease Abhik Kumar Ray, Parth Sarthi Sen Gupta, Saroj Kumar Panda, Satyaranjan Biswal, Malay Kumar Rana
Research
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 Xuping Xie, Antonio E. Muruato, Xianwen Zhang, Kumari G. Lokugamage, Camila R. Fontes-Garfias, Jing Zou, Jianying Liu, Ping Ren, Mini Balakrishnan, Tomas Cihlar, Chien-Te K. Tseng, Shinji Makino, Vineet D. Menachery, John P. Bilello, Pei-Yong Shi
Research
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2. Anwaar, Muhammad U.Adnan, FarjadAbro, AsmaKhan, Rayyan A.Rehman, Asad U.Osama, MuhammadRainville, ChristopherKumar, SureshSterner, DavidJaved, SaadJamal, Syed B.Baig, AhmadullahShabbir, Muhammad R.Ahsan, WasehButt, Tauseef R.Assir, Muhammad Z.
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
